Company profile

Ticker
DGX
Exchange
CEO
Stephen H. Rusckowski
Employees
Incorporated in
Location
Fiscal year end
Former names
Corning Clinical Laboratories Inc
SEC CIK
IRS number
161387862

DGX stock data

(
)

Calendar

4 May 20
2 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Mar 20 Dec 19 Sep 19 Jun 19
Revenue 1.82B 1.93B 1.96B 1.95B
Net income 106M 265M 226M 239M
Diluted EPS 0.73 1.86 1.56 1.66
Net profit margin 5.82% 13.76% 11.55% 12.24%
Operating income 175M 363M 313M 307M
Net change in cash -850M 758M 161M -191M
Cash on hand 342M 1.19B 434M 273M
Cost of revenue 1.27B 1.26B 1.26B 1.27B
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 7.73B 7.53B 7.4B 7.21B
Net income 906M 788M 824M 696M
Diluted EPS 6.28 5.29 5.5 4.51
Net profit margin 11.73% 10.46% 11.13% 9.65%
Operating income 1.23B 1.1B 1.17B 1.28B
Net change in cash 1.06B -2M -222M 226M
Cash on hand 1.19B 135M 137M 359M
Cost of revenue 5.04B 4.93B 4.72B 4.62B

Financial data from company earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
8 Jun 20 Ring Timothy M Common Stock Option exercise Aquire M 58.37 532 31.05K 23,584
8 Jun 20 Guinan Mark Common Stock Sell Dispose S 118.604 8,524 1.01M 73,579
8 Jun 20 Guinan Mark Common Stock Sell Dispose S 116.811 45,826 5.35M 100,349
8 Jun 20 Guinan Mark Common Stock Option exercise Aquire M 71.17 72,596 5.17M 146,175
8 Jun 20 Guinan Mark Non-Qualifed Stock Option Common Stock Option exercise Dispose M 71.17 72,596 5.17M 0
8 Jun 20 Ring Timothy M Common Stock Sell Dispose S 116.6 11,730 1.37M 20,505
8 Jun 20 Ring Timothy M Common Stock Option exercise Aquire M 63.42 779 49.4K 32,235
8 Jun 20 Ring Timothy M Common Stock Option exercise Aquire M 60.215 790 47.57K 31,456
8 Jun 20 Ring Timothy M Common Stock Option exercise Aquire M 57.565 6,111 351.78K 30,666
8 Jun 20 Ring Timothy M Common Stock Option exercise Aquire M 61.615 820 50.52K 24,555
88.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 688 692 -0.6%
Opened positions 103 94 +9.6%
Closed positions 107 64 +67.2%
Increased positions 245 244 +0.4%
Reduced positions 234 226 +3.5%
13F shares
Current Prev Q Change
Total value 9.47B 12.74B -25.7%
Total shares 118.63M 119.17M -0.5%
Total puts 525.5K 311.9K +68.5%
Total calls 663.8K 432.4K +53.5%
Total put/call ratio 0.8 0.7 +9.8%
Largest owners
Shares Value Change
Vanguard 15.76M $1.27B +2.4%
BLK BlackRock 12.86M $1.03B -1.8%
STT State Street 6.82M $547.55M +2.7%
American Century Companies 5.26M $422.59M -5.5%
Fiduciary Management 4.66M $374.05M +1.5%
Davis Selected Advisers 3.87M $310.51M -1.0%
Victory Capital Management 3.53M $283.46M -12.4%
JPM JPMorgan Chase & Co. 2.97M $238.62M +29.6%
Geode Capital Management 2.2M $176.57M +1.0%
Dimensional Fund Advisors 1.91M $153.78M -1.4%
Largest transactions
Shares Bought/sold Change
Boston Partners 0 -1.99M EXIT
Norges Bank 0 -1.39M EXIT
Grantham, Mayo, Van Otterloo & Co. 1.37M +1.37M NEW
Marshall Wace North America 1.21M -1.06M -46.8%
Scharf Investments 711.96K +711.96K NEW
JPM JPMorgan Chase & Co. 2.97M +678.62K +29.6%
Schroder Investment Management 457.24K -506.08K -52.5%
Victory Capital Management 3.53M -499.48K -12.4%
FIL 805.42K -453.09K -36.0%
FRLG Goldman Sachs 789.01K -416.32K -34.5%

Financial report summary

?
Risks
  • The U.S. healthcare system is evolving and medical laboratory testing market fundamentals are changing, and our business could be adversely impacted if we fail to adapt.
  • The clinical testing business is highly competitive, and if we fail to provide an appropriately priced level of service or otherwise fail to compete effectively it could have a material adverse effect on our revenues and profitability.
  • Government payers, such as Medicare and Medicaid, have taken steps to reduce the utilization and reimbursement of healthcare services, including clinical testing services.
  • Health plans and other third parties have taken steps to reduce the utilization and reimbursement of health services, including clinical testing services.
  • Government payers and third parties, including health plans, may not recognize the value of, or compensate or reimburse us for, new and innovative solutions.
  • Our business operations and reputation may be materially impaired if we do not comply with privacy laws or information security policies.
  • Our business could be negatively affected if we are unable to continue to improve our efficiency.
  • Business development activities are inherently risky and integrating our operations with businesses we acquire may be difficult.
  • We are subject to numerous legal and regulatory requirements governing our activities, and we may face substantial fines and penalties, and our business activities may be impacted, if we fail to comply.
  • Our business could be adversely impacted by the FDA's approach to regulation.
  • Failure to accurately bill for our services, or to comply with applicable laws relating to government healthcare programs, could have a material adverse effect on our business.
  • Hardware and software failures or delays in our information technology systems, including failures resulting from our systems conversions or otherwise, could disrupt our operations and cause the loss of confidential information, customers and business opportunities or otherwise adversely impact our business.
  • The IT systems that we rely on may be subject to unauthorized tampering, cyberattack or other security breach.
  • Failure to develop, or acquire licenses for, new tests, technology and services could negatively impact our testing volume and revenues.
  • We may be unable to obtain, maintain or enforce our intellectual property rights and may be subject to intellectual property litigation that could adversely impact our business.
  • The development of new technologies (including artificial intelligence technologies) may impact the healthcare industry, and the development of new, more cost-effective solutions that can be performed by our customers or by patients, and the continued internalization of testing by hospitals or clinicians, could negatively impact our testing volume and revenues.
  • Our outstanding debt may impair our financial and operating flexibility.
  • Our ability to attract and retain qualified employees is critical to the success of our business and the failure to do so may materially adversely affect our performance.
  • Failure to establish, and perform to, appropriate quality standards to assure that the appropriate standard of quality is observed in the performance of our diagnostic information services could adversely affect the results of our operations and adversely impact our reputation.
  • We are subject to numerous political, legal, operational and other risks as a result of our international operations which could impact our business in many ways.
  • Our operations may be adversely impacted by the effects of natural disasters such as hurricanes and earthquakes, public health emergencies and health pandemics, hostilities or acts of terrorism and other criminal activities.
  • Adverse results in material litigation could have an adverse financial impact and an adverse impact on our client base and reputation.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accurately, affirmative, agreement, Aid, antibody, assigned, assist, begun, Blueprint, burden, cancelation, cancellation, capable, capped, case, catalyst, cessation, challenge, complaint, comply, constitute, coordinated, correct, country, covenant, curtailing, customary, deadline, deemed, deep, default, delay, Department, deteriorated, difficult, diminished, dismissed, distancing, distributed, division, duration, ease, eased, EBITDA, economy, employer, event, exacerbate, expertise, expressed, extra, face, failure, fee, Fitch, frequently, function, gene, genetic, global, guarantee, guidance, hand, Hermann, Human, immaterial, inclusive, incurrence, Interbank, Investor, legislation, light, line, local, London, lost, macroeconomic, meet, metric, metro, moderated, Moody, moved, negotiated, noncompliance, Oy, pandemic, pay, payroll, persist, plant, pocket, pool, Poor, preserve, proceeding, prolonged, pronouncement, proprietary, provision, Pursuant, ratio, recessionary, recoverability, regulatory, relevant, remote, repayment, reprieve, response, retention, retirement, review, safe, safety, salary, scope, sector, select, selective, sequencing, sequestration, significantly, small, Southeast, specialty, strain, supply, suspended, suspending, suspension, sustained, technical, temporarily, temporary, thousand, tranche, transmission, travel, unable, unprecedented, utilization, utilized, variant, voluntarily, vulnerable, warrant, wholesale, withdrawn, worse
Removed: achieved, ASU, bad, benchmark, Blue, Cape, carry, classification, Clifton, Cod, commencement, comparative, dependent, designated, determining, equally, Examination, execute, expanded, extend, fixed, foreseeable, fourth, goal, Horizon, ii, index, inflation, initially, leased, lessee, liquid, logistic, minimum, offering, opening, overnight, package, periodically, permitted, planned, practical, previously, productivity, prospectively, rank, redesignated, refer, renewal, rent, rental, repaid, repatriation, repay, ReproSource, requirement, restate, retained, retrospectively, settled, Shield, shorter, single, sinking, space, unchanged, UnitedHealthcare